NCT05376813 (SEGMENTATION) is a NA clinical trial of CT-Scan and MRI in Reverse Shoulder Prosthesis, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT05376813?

NCT05376813 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT05376813?

Interventions in NCT05376813: CT-Scan and MRI.

What condition does NCT05376813 study?

NCT05376813 studies Reverse Shoulder Prosthesis.

Is NCT05376813 still recruiting?

NCT05376813 is currently withdrawn. Last updated 19 March 2025.

Last reviewed 2025-03-19 · How we verify

NCT05376813: SEGMENTATION

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Algorithm Creation by Automated Segmentation by MRI for Bone and Muscles of Shoulder

Withdrawn NA Last updated 19 March 2025

What this trial tests

NA trial testing CT-Scan and MRI in Reverse Shoulder Prosthesis. Withdrawn.

Timeline

31 August 2023

Primary endpoint
28 April 2024

28 April 2024

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Start date	31 August 2023
Primary completion	28 April 2024
Estimated completion	28 April 2024

Drugs / interventions tested

CT-Scan and MRI

Conditions studied

Reverse Shoulder Prosthesis — all drugs for Reverse Shoulder Prosthesis →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Reverse Shoulder Prosthesis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of the study is to develop an algorithm of automated segmentation of shoulder by MRI examinations.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05376813 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 19 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05376813.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing